The information contained within this section of the website is for the purposes of AIM Rule 26.
Feedback plc (AIM: FDBK) was founded in 1958 and has been listed on the AIM market of the London Stock Exchange since 2007.
Feedback plc is a specialist medical imaging technology company providing innovative software and systems through its fully owned trading subsidiary, Feedback Medical Limited.
Feedback is a group of companies which aims to liberate clinicians. We do this by thinking differently and offering safer, secure and simpler alternatives to the traditional ways of working.
We are focused on driving better outcomes for clinicians and patients. We produce innovative technology that enhances clinical communication, accessing and storing medical information. Our vision is realised in Bleepa®, our flagship product that is changing the way that clinicians discuss patient cases, access information such as medical images and even where they can work from.
Our proprietary technologies are Bleepa®; CareLocker, patient-centric cloud architecture; TexRAD, the quantitative texture analysis tool; and Cadran, a picture archiving communication system (PACS).
Bleepa® is a secure instant messaging system which facilitates the sharing of clinical-grade medical images between personal devices, such as smartphones and tablets. Developed by Feedback Medical, Bleepa’s unique technology allows the discussion, review and decision-making surrounding clinical-grade images to happen in real time, from any location. This powerful technology has the potential to revolutionise the speed and quality of patient management, changing the lives and practices of doctors all across the world.
CareLocker is a patient-centric cloud store of data available to any care setting and to the patient in a mobile app. It enables patients to have more control over their healthcare data in a safe, secure platform, allowing them to share that data with their clinician. For care settings, it offers opportunities for improved storage optimisation making it more cost-effective than traditional data storage architectures. CareLockers can be built on a patient-by-patient basis, allowing organisations to transition to a cloud architecture as patients enter care pathways rather than having to undertake mass data migrations.
TexRAD is a patent-protected software tool which extracts and quantifies texture features in radiological images, assisting research into all tumour types. In the exciting new field of radiomics, TexRAD uncovers biomarkers in medical images which are invisible to the naked eye. TexRAD has featured in over 100 academic publications, won numerous awards and is currently used in over 50 prestigious institutions worldwide. Feedback Medical have recently launched TexRAD Lung, a software tool for the analysis of lung cancer, which is CE marked for clinical use in the EU.
The Cadran image platform provides hospitals and research institutes with a comprehensive picture archiving communication system (PACS) for medical images. It equips users with a flexible, convenient and secure platform for image handling from all imaging modalities, such as CT and PET scanners. Cadran originates from developments by professionals working in real-life medical environments and has been advanced in close cooperation with researchers, radiologists and healthcare IT specialists to ensure user confidence and relevance in today’s medical world. Cadran Viewer is a Medical Device which is CE marked for clinical use in the EU.
View information on the company directors here.
View information on corporate governance here.
The Company is a public company incorporated in the UK and has its place of central management and control in the UK. Accordingly, the Takeover Code applies to the Company and, as a result, Shareholders are entitled to the benefits of the takeover offer protections provided under the Takeover Code.
Country of incorporation: England and Wales
Company registration number: 598696
Main country of operation: United Kingdom
View the Annual Reports and Accounts here for the last three years.
There are no restrictions on the transfer of ordinary shares.
The securities of the Company are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.
AIM securities in issue: As at 4 September 2023 there were 13,334,659 ordinary shares in issue. The Company does not hold any shares in treasury.
As at 4 September 2023, the percentage of shares not held in public hands and insofar as the Company is aware (as defined by AIM rule 26) was 67.88%.
View the identity and shareholdings of the Company’s significant shareholders here.
View all Company Advisor Information here.
This information was last updated on 4 September 2023.